Skip to main content
OpenTrials
Completed

NCT Number: NCT03239379

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

This study is a single-center, randomized, single-blind, placebo (PBO)-controlled, multiple-dose study to characterize the safety, tolerability, PK, and PD of IV BNZ-1 administered to healthy adult subjects once weekly (QW) for 4 doses or once every other week (QOW) for 3 doses. Five cohorts of 6 subjects randomized 5 BNZ-1:1 PBO are planned to be enrolled in the trial. Participants will be followed for 4 weeks after the last dose for safety monitoring, and collection of PK and PD samples.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Celerion

Tempe, Arizona, 85283, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-smoker.
  • Weight ≤100 kg (due to drug supply limitations).
  • Body Mass Index (BMI) ≥19 and <35 kg/m2.
  • Healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, vital signs (pulse rate, blood pressure, respiratory rate), and ECG.
  • Willing and able to consent and participate in the study.
  • Subject agrees not to receive any other investigational product or therapy while participating in this study.
  • Agrees to use adequate effective birth control methods prior to, during and for 30 days after the study.

Exclusion criteria

  • Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, renal, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator.
  • History of cancer (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved).
  • History of or currently active primary or secondary immunodeficiency.
  • Known active bacterial, viral, fungal, mycobacterial infection, or other infection (including tuberculosis [TB] or atypical mycobacterial disease [but excluding fungal infection of nail beds, minor upper respiratory tract infection, and minor skin conditions]), or any major episode of infection that required hospitalization or treatment with IV antibiotics within 30 days of screening or oral antibiotics within 14 days prior to screening.
  • Subject has received other investigational products or therapy in the past 30 days prior to study drug administration.
  • Serologic evidence of human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.
  • Subject has received an immunization within 14 days prior to study drug administration.
  • History of alcohol or drug abuse within 1 year prior to screening.
  • Subject requires the ongoing use of prescription medication other than oral contraceptives.

Treatment and study plan

BNZ132-1-40

Drug

Injectable peptide antagonist of IL-2, IL-9 and IL-15

Other names: BNZ-1

Placebo

Drug

Normal Saline

Primary outcomes

  1. Incidence, severity and relationship of treatment-emergent adverse events

    Time frame: 8 weeks

    general safety evaluation by principal investigator

Secondary outcomes

  1. single-dose and steady state Cmax

    Time frame: 8 weeks

    plasma concentrations collected at multiple times after the first and last doses

  2. single-dose and steady state AUC0-t

    Time frame: 8 weeks

    plasma concentrations collected at multiple times after the first and last doses

  3. Steady-state Elimination half-life (t1/2)

    Time frame: 8 weeks

    plasma concentrations collected at multiple times after the last dose

  4. Change from baseline for Regulatory T-cells (Tregs)

    Time frame: 8 weeks

    Flow cytometry of PBMCs at multiple time points post dose

  5. Change from baseline for Natural Killer Cells

    Time frame: 8 weeks

    Flow cytometry of PBMCs at multiple time points post dose

  6. Change from baseline for CD8+ central memory T-cells (Tcm)

    Time frame: 8 weeks

    Flow cytometry of PBMCs at multiple time points post dose

Sponsors and collaborators

Lead sponsor

Bioniz Therapeutics

Industry

Collaborators

  • Celerion

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Aug 4, 2017
Registry last updated
May 15, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.